# LAI Weekly Newsletter - Week of 2025-12-22

**Generated:** December 22, 2025 | **Items:** 5 signals | **Coverage:** 1 sections

## üéØ TL;DR
‚Ä¢ The FDA has approved an expanded indication for Teva's UZEDY¬Æ (risperidone) long-acting injectable, while Teva is also preparing for a US NDA submission for another LAI product.

‚Ä¢ Significant partnerships were announced between Nanexa and Moderna for LAI development, and Medincell received a grant to advance its LAI technology.

‚Ä¢ Regulatory and clinical milestones were achieved by Teva and Medincell, highlighting continued progress in the LAI space.

## üì∞ Introduction
This week's LAI newsletter covers the top 5 signals shaping the long-acting injectable ecosystem, providing executives with critical insights into emerging trends, partnerships, and regulatory developments impacting this rapidly evolving space.

---

## üî• Top Signals ‚Äì LAI Ecosystem
*5 items ‚Ä¢ Sorted by score*

### üìã The FDA has approved an expanded indication for UZEDY¬Æ (risperidone) Extended-Release Injectable Sus
**Source:** press_corporate__medincell ‚Ä¢ **Score:** 11.7 ‚Ä¢ **Date:** Dec 22, 2025

The FDA has approved an expanded indication for UZEDY¬Æ (risperidone) Extended-Release Injectable Suspension as a treatment for adults living with Bipolar I Disorder. UZEDY is a long-acting injectable formulation of risperidone.

**Key Players:**  ‚Ä¢ **Technology:** Extended-Release Injectable

[**Read more ‚Üí**](https://www.medincell.com/wp-content/uploads/2025/10/MDC_UZEDY-BDI_EN_10102025_vf.pdf)


---

### üìã Teva Pharmaceuticals has submitted a New Drug Application to the U.S. FDA for Olanzapine Extended-Re
**Source:** press_corporate__medincell ‚Ä¢ **Score:** 11.2 ‚Ä¢ **Date:** Dec 22, 2025

Teva Pharmaceuticals has submitted a New Drug Application to the U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK), a once-monthly treatment for schizophrenia in adults developed in partnership with Medincell.

**Key Players:** Medincell, Teva Pharmaceuticals ‚Ä¢ **Technology:** Extended-Release Injectable, Once-Monthly

[**Read more ‚Üí**](https://www.medincell.com/wp-content/uploads/2025/12/MDC_Olanzapine-NDA-filing_09122025_EN_vf-2.pdf)


---

### ü§ù Nanexa and Moderna have entered into a license and option agreement for the development of up to fiv
**Source:** press_corporate__nanexa ‚Ä¢ **Score:** 11.0 ‚Ä¢ **Date:** Dec 22, 2025

Nanexa and Moderna have entered into a license and option agreement for the development of up to five undisclosed compounds using Nanexa's PharmaShell¬Æ technology. Nanexa will receive an upfront payment and is eligible for milestone payments and royalties.

**Key Players:** Nanexa, Moderna ‚Ä¢ **Technology:** PharmaShell¬Æ

[**Read more ‚Üí**](https://nanexa.com/mfn_news/nanexa-and-moderna-enter-into-license-and-option-agreement-for-the-development-of-pharmashell-based-products/)


---

### üß¨ Teva's UZEDY¬Æ continues strong growth, and the company is preparing for a US NDA submission for its 
**Source:** press_corporate__medincell ‚Ä¢ **Score:** 9.0 ‚Ä¢ **Date:** Dec 22, 2025

Teva's UZEDY¬Æ continues strong growth, and the company is preparing for a US NDA submission for its Olanzapine Long-Acting Injectable (LAI) in Q4 2025.

**Key Players:** Teva ‚Ä¢ **Technology:** Long-Acting Injectable

[**Read more ‚Üí**](https://www.medincell.com/wp-content/uploads/2025/11/PR_MDC_Teva-earnings-Q3_2025_05112025_vf.pdf)


---

### üí∞ Medincell, a biotech company, has been awarded a new grant to develop long-acting injectable formula
**Source:** press_corporate__medincell ‚Ä¢ **Score:** 5.8 ‚Ä¢ **Date:** Dec 22, 2025

Medincell, a biotech company, has been awarded a new grant to develop long-acting injectable formulations to fight malaria.

**Key Players:** Medincell ‚Ä¢ **Technology:** Long-Acting Injectable

[**Read more ‚Üí**](https://www.medincell.com/wp-content/uploads/2025/11/MDC_Gates-Malaria_PR_24112025_vf.pdf)


---

## üìä Newsletter Metrics
- **Total Signals:** 5 items processed
- **Sources:** 2 unique sources
- **Key Players:** Teva, Nanexa, Medincell, Teva Pharmaceuticals, Moderna
- **Technologies:** Long-Acting Injectable, Once-Monthly, Extended-Release Injectable
- **Generated:** 2025-12-22T09:29:35.098584Z
